The HeartInsight algorithm combines heart failure parameters into a predictive score and alerts physicians if a patient with an implanted ICD or CRT-D is at higher risk of hospitalization. Biotronik will roll out HeartInsight in Europe in April.
Biotronik announced the European launch of its HeartInsight remote heart failure management solution, an algorithm that accurately identifies patients at higher risk of heart-failure decompensation and helps physicians keep heart failure patients out of the hospital.
HeartInsight recently received a CE mark and the company plans to present the algorithm to clinicians for the first time...
Create an account to read this article
Already a subscriber?
Haemonetics will acquire Quebec-based OpSens for CAD $2.90 per share, or about US $253m at current exchange rates. Haemonetics expects OpSens' fiber-optic technology to complement its interventional cardiology portfolio.
The retail giant will sell the Dexcom G7 continuous glucose monitoring system to eligible customers through a new online platform.
Stimdia is trying to restore respiratory function in ICU patients with phrenic nerve stimulation.
Reuters reported that global private equity firm Carlyle Group has offered to pay at least $7bn for Medtronic’s patient monitoring and respiratory interventions businesses. Medtronic announced its plan to get out of those businesses about one year ago.
Synchron is preparing a pilot study of its fully wireless, second-gen brain-computer interface after an ALS patient controlled an iPad solely by thought. If all goes as planned, Synchron’s BCI will move into pivotal trials in 2026.
Apreo Health CEO Karun Naga talks to Medtech Insight about the company’s intentions for its Series B funding. The Breathe-3 clinical trial and early commercialization activities, involving physician education, are top priorities.
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
